

# Press Release



## ASKA Pharmaceutical Co., Ltd. and Harbin Pharmaceutical Group Co., Ltd Enter into Exclusive License Agreement in China

**TOKYO, January 7th, 2021** - ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo, President: Takashi Yamaguchi, hereinafter "ASKA") and Harbin Pharmaceutical Group Co., Ltd. (Heilongjiang Province, China, CEO: Helen Chui, hereinafter "Hayao") signed an Exclusive License Agreement in China for the H<sub>2</sub> receptor antagonist ALTAT<sup>®</sup> (generic name: Roxatidine Acetate Hydrochloride, dosage form: Injection, Capsule, Fine Granules) developed and sold by ASKA.

### 1. Business Rationale for the Agreement

With the conclusion of this agreement, ASKA will receive an upfront payment from Hayao and the right to receive royalties according to sales, in exchange for granting the exclusive sales right of ALTAT<sup>®</sup> in China.

Aiming for the continuous growth and development of our company through the development of overseas business, the International Business Division was established in April 2020 and started its activities in earnest. With this agreement as one of the footholds, we will further accelerate business development in the Asian region.

### 2. Overview of Hayao

Company Name	Harbin Pharmaceutical Group Co., Ltd. (哈药集团股份有限公司)
Establishment	1991
Address	7 Qunli Road, Daoli District, Harbin City, Heilongjiang Province, The People's Republic of China
Capital (FY 2019)	2.5 billion CNY (39.8 billion yen*)
Employees (FY 2019)	14,295 employees
Net Sales (FY 2019)	11.8 billion CNY (187.7 billion yen*)
Businesses	Manufacturing, sales and import of antibiotics, Chinese herbs, chemicals, OTC drugs and veterinary drugs
URL	<a href="http://en.hayao.com/">http://en.hayao.com/</a>

\*1CNY=15.88JPY(as of January 4, 2021)

### 3. Future Financial Outlook

The impact of this agreement on consolidated results of ASKA for FY 2020 will be minor.